NIDA Drug Use Screening Tool: Legacy Process and TAPS Replacement

The NIDA Drug Use Screening Tool is a discontinued legacy workflow that paired the NIDA Quick Screen with the NIDA-modified ASSIST, also called NMASSIST. NIDA's current materials direct clinicians toward newer validated tools such as TAPS; the former workflow is useful as historical context but should not be selected for current screening.

ASSIST remains the World Health Organization's multi-substance questionnaire, while NIDA's former workflow adapted that instrument for a different clinical process. NIDA now marks its adapted screening tool as discontinued, so current tool selection should follow NIDA's active screening chart.

What was the NIDA Quick Screen?

The NIDA Quick Screen was the first step in a brief adult medical-setting workflow that asked about substance use frequency during the past year. It covered alcohol, tobacco, prescription medication misuse, and illicit drug use before deciding whether more detailed questions were needed.

The Quick Screen was a triage step, not a diagnostic interview and not a biological test. A positive response identified a reason to continue the conversation.

What was NMASSIST?

NMASSIST was the NIDA-modified Alcohol, Smoking and Substance Involvement Screening Test used after the initial screen identified relevant use. It adapted the structure of the World Health Organization's ASSIST questionnaire to ask about substances used, recent patterns, problems, risk of harm, dependence-related experiences, and injection-related risk.

The historical instrument adapted the WHO ASSIST structure for general medical settings and adults age 18 or older. Its score suggested an intervention level; it did not establish a DSM diagnosis.

How did the legacy NIDA workflow work?

The legacy workflow moved from a brief frequency question to substance-specific follow-up and then to feedback, brief intervention, or referral. The sequence limited detailed questioning to people whose first responses indicated possible risk.

1. Quick Screen: ask about past-year substance use frequency.
2. NMASSIST follow-up: identify the substance and ask about recent use, consequences, control, and harm.
3. Risk interpretation: review the substance involvement score with the person.
4. Clinical response: provide feedback, brief intervention, or referral for assessment when indicated.

Why was the NIDA Drug Use Screening Tool discontinued?

NIDA marks the legacy NIDA Drug Use Screening Tool as discontinued because the current screening landscape uses newer validated instruments and updated workflows. A historical page should not imply that an unavailable or retired tool is the preferred current choice.

Discontinued status also limits what can responsibly be claimed about availability, scoring interfaces, and current clinical support. Readers should verify the current instrument and workflow with a qualified healthcare organization.

What replaced the NIDA Quick Screen and NMASSIST?

NIDA’s current screening resources include TAPS, a two-step screen and brief assessment for tobacco, alcohol, prescription medication misuse, and other substance use. TAPS-1 asks about past-year frequency, and TAPS-2 asks more detailed questions when use is reported.

The replacement decision depends on age, substances, setting, language, workflow, and the ability to provide follow-up. The replacement is not a reason to merge this historical page with every current screening tool.

How does the legacy NIDA workflow differ from DAST-10?

The NIDA workflow began with broad adult substance-use frequency questions and escalated to substance-specific follow-up, while DAST-10 asks ten past-year questions about drug-related problems. Their scopes overlap, but they are not the same questionnaire and their historical instructions should not be combined.

The DAST-10 remains a current drug-problem questionnaire with ten past-year questions, a defined score, and limits that differ from the discontinued NIDA workflow.

What are the limits of the legacy NIDA tool?

The legacy tool is limited by discontinued status, self-report bias, changing clinical workflows, incomplete disclosure, and the absence of a diagnostic examination. It cannot measure drug concentration, current impairment, withdrawal severity, or medical instability.

A historical score should not be used to determine current treatment by itself. Current concerns require a validated tool, clinical assessment, and a response that matches immediate safety and care needs.